Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Townsquare Capital LLC

Townsquare Capital LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,836 shares of the biopharmaceutical company’s stock after purchasing an additional 613 shares during the quarter. Townsquare Capital LLC’s holdings in Halozyme Therapeutics were worth $4,964,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after purchasing an additional 200 shares in the last quarter. State of New Jersey Common Pension Fund D raised its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after purchasing an additional 302 shares during the period. Parkside Financial Bank & Trust boosted its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV grew its holdings in Halozyme Therapeutics by 2.4% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 328 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 4.4 %

HALO opened at $60.22 on Monday. The firm has a market capitalization of $7.44 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company’s 50 day simple moving average is $60.22 and its two-hundred day simple moving average is $54.91. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HALO. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.